JP2018524307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524307A5 JP2018524307A5 JP2017564733A JP2017564733A JP2018524307A5 JP 2018524307 A5 JP2018524307 A5 JP 2018524307A5 JP 2017564733 A JP2017564733 A JP 2017564733A JP 2017564733 A JP2017564733 A JP 2017564733A JP 2018524307 A5 JP2018524307 A5 JP 2018524307A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- pxrd pattern
- pattern shown
- crystal
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 claims description 43
- FEQOLYDPQKHFTD-UHFFFAOYSA-N 1-(2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine;hydrochloride Chemical compound Cl.CN(C)CC1CCOC1(C=1C=CC=CC=1)C1=CC=CC=C1 FEQOLYDPQKHFTD-UHFFFAOYSA-N 0.000 claims description 31
- 238000001144 powder X-ray diffraction data Methods 0.000 claims description 29
- 239000002207 metabolite Substances 0.000 claims description 19
- 239000002245 particle Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 208000024827 Alzheimer disease Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 230000000324 neuroprotective effect Effects 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 238000001157 Fourier transform infrared spectrum Methods 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- 238000005160 1H NMR spectroscopy Methods 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023070740A JP7492781B2 (ja) | 2015-07-22 | 2023-04-24 | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195486P | 2015-07-22 | 2015-07-22 | |
| US62/195,486 | 2015-07-22 | ||
| PCT/IB2016/001181 WO2017013498A2 (en) | 2015-07-22 | 2016-07-19 | Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021018132A Division JP2021073300A (ja) | 2015-07-22 | 2021-02-08 | テトラヒドロ−ｎ，ｎ−ジメチル−２，２−ジフェニル−３−フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物 |
| JP2023070740A Division JP7492781B2 (ja) | 2015-07-22 | 2023-04-24 | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524307A JP2018524307A (ja) | 2018-08-30 |
| JP2018524307A5 true JP2018524307A5 (enExample) | 2019-08-29 |
| JP7304043B2 JP7304043B2 (ja) | 2023-07-06 |
Family
ID=57833871
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564733A Active JP7304043B2 (ja) | 2015-07-22 | 2016-07-19 | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物 |
| JP2021018132A Pending JP2021073300A (ja) | 2015-07-22 | 2021-02-08 | テトラヒドロ−ｎ，ｎ−ジメチル−２，２−ジフェニル−３−フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物 |
| JP2023070740A Active JP7492781B2 (ja) | 2015-07-22 | 2023-04-24 | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021018132A Pending JP2021073300A (ja) | 2015-07-22 | 2021-02-08 | テトラヒドロ−ｎ，ｎ−ジメチル−２，２−ジフェニル−３−フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物 |
| JP2023070740A Active JP7492781B2 (ja) | 2015-07-22 | 2023-04-24 | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10413519B2 (enExample) |
| EP (2) | EP4616852A3 (enExample) |
| JP (3) | JP7304043B2 (enExample) |
| CN (2) | CN108026059A (enExample) |
| CA (1) | CA2986349A1 (enExample) |
| HK (1) | HK1247926A1 (enExample) |
| WO (1) | WO2017013498A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10426754B2 (en) | 2017-06-14 | 2019-10-01 | Anavex Life Sciences Corp. | Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease |
| JP2020523417A (ja) * | 2017-06-14 | 2020-08-06 | アナベックス ライフ サイエンス コーポレイション | アルツハイマー病の治療のためのａｎａｖｅｘ２−７３ |
| WO2019200345A1 (en) * | 2018-04-12 | 2019-10-17 | Anavex Life Sciences Corp. | A2-73 crystalline polymorph compositions of matter and methods of use thereof |
| JP7582869B2 (ja) | 2018-05-18 | 2024-11-13 | アナベックス ライフ サイエンス コーポレイション | レスポンダ選択および治療の最適化されたｓｉｇｍａ－１アゴニスト方法 |
| US12473268B2 (en) | 2020-02-04 | 2025-11-18 | Assia Chemical Industries, Ltd. | Solid state forms of Blarcamesine salts |
| EP4516782A4 (en) * | 2022-04-29 | 2025-06-11 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF BLARCAMESIN HYDROCHLORIDE, ITS PREPARATION PROCESS AND ITS USE |
| US12018005B1 (en) * | 2023-07-25 | 2024-06-25 | Egis Gyógyszergyár Zrt. | Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| GB9413202D0 (en) | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| GR1002616B (el) * | 1996-02-21 | 1997-02-20 | Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης. | |
| GB9703673D0 (en) | 1997-02-21 | 1997-04-09 | Bradford Particle Design Ltd | Method and apparatus for the formation of particles |
| GB9804379D0 (en) | 1998-03-02 | 1998-04-22 | Bradford Particle Design Ltd | Method of particle formation |
| GB9810559D0 (en) | 1998-05-15 | 1998-07-15 | Bradford Particle Design Ltd | Method and apparatus for particle formation |
| GB9915975D0 (en) | 1999-07-07 | 1999-09-08 | Bradford Particle Design Ltd | Method for the formation of particles |
| GB0009803D0 (en) * | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
| TW586963B (en) | 2001-07-20 | 2004-05-11 | Nektar Therapeutics Uk Ltd | Method and apparatus for preparing target substance in particulate form and fluid inlet assembly for said apparatus |
| US7368468B2 (en) | 2003-06-18 | 2008-05-06 | Teva Pharmaceutical Industries Ltd. | Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them |
| GR1006794B (el) | 2009-02-26 | 2010-06-04 | Αλεξανδρος Βαμβακιδης | Προσδετες των σιγμα υποδοχεων, αντι-αποπτωτικες και προ-αποπτωτικες ιδιοτητες επι των κυτταρικων μηχανισμων, και με πρωτοτυπη κυτταρο-προστατευτικη αλλα και αντικαρκινικη δραση |
| GB201005623D0 (en) * | 2010-04-01 | 2010-05-19 | Vantia Ltd | New polymorph |
| GR1007686B (el) * | 2011-07-08 | 2012-09-12 | Αλεξανδρος Δημητριου Βαμβακιδης | Συνθεση των (+) και (-) 1-(5,5-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης, (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης και (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν-μεθυλομεθυλαμινης |
| CN103539783A (zh) * | 2012-07-12 | 2014-01-29 | 江苏恒瑞医药股份有限公司 | 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法 |
| GR1008233B (el) | 2013-03-28 | 2014-06-23 | Αλεξανδρος Δημητριου Βαμβακιδης | Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες |
| JP7429942B2 (ja) | 2015-07-22 | 2024-02-09 | アナベックス ライフ サイエンシズ コーポレイション | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用 |
| US10426754B2 (en) | 2017-06-14 | 2019-10-01 | Anavex Life Sciences Corp. | Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease |
-
2016
- 2016-07-19 CN CN201680033152.9A patent/CN108026059A/zh active Pending
- 2016-07-19 CN CN202411518463.7A patent/CN119390667A/zh active Pending
- 2016-07-19 US US15/579,705 patent/US10413519B2/en active Active
- 2016-07-19 HK HK18107440.1A patent/HK1247926A1/zh unknown
- 2016-07-19 EP EP25193445.1A patent/EP4616852A3/en active Pending
- 2016-07-19 JP JP2017564733A patent/JP7304043B2/ja active Active
- 2016-07-19 EP EP16827324.1A patent/EP3325456B1/en active Active
- 2016-07-19 WO PCT/IB2016/001181 patent/WO2017013498A2/en not_active Ceased
- 2016-07-19 CA CA2986349A patent/CA2986349A1/en active Pending
-
2019
- 2019-07-29 US US16/525,319 patent/US10966952B2/en active Active
-
2021
- 2021-02-08 JP JP2021018132A patent/JP2021073300A/ja active Pending
- 2021-04-05 US US17/222,611 patent/US11661405B2/en active Active
-
2023
- 2023-04-24 JP JP2023070740A patent/JP7492781B2/ja active Active
- 2023-05-08 US US18/313,723 patent/US20230278973A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524307A5 (enExample) | ||
| PH12020500265A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| JP2013519675A5 (enExample) | ||
| JP2017071634A5 (enExample) | ||
| JP2016512563A5 (enExample) | ||
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| JP2016518337A5 (enExample) | ||
| CN110036005A (zh) | 酰胺衍生物及其在药物中的应用 | |
| JP2015038149A5 (enExample) | ||
| JP2016513734A5 (enExample) | ||
| JP2016515522A5 (enExample) | ||
| JP2015057451A5 (enExample) | ||
| CN110139865A (zh) | Fgfr抑制剂 | |
| RU2017112747A (ru) | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции | |
| JP2016540749A5 (enExample) | ||
| JP2016512817A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JP2017537912A5 (enExample) | ||
| CN111566100A (zh) | 嘧啶类化合物、其制备方法及其医药用途 | |
| CN110799501A (zh) | 一种食欲素受体拮抗剂的晶型及其制备方法和用途 | |
| JP2015522603A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| JP2013523758A5 (enExample) | ||
| JP2007119497A5 (enExample) |